Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia

• Status: Unknown status
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of the present study is to evaluate the effect of D-serine, added to antipsychotic treatment, on negative and cognitive symptoms in schizophrenia.

The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center
• Collaborator: Stanley Medical Research Institute

Criteria

Inclusion Criteria:

• Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) diagnosis of schizophrenia and\or schizoaffective disorder.

• Age between 18 to 64.

• PANSS negative symptom score higher than 19.

• SAS total score lower than 12.

• CDSS suicidal risk lower than 2

Exclusion Criteria:

• Epilepsy

• Meets DSM-IV criteria for mental retardation.

• Medical condition which confounds presentation or treatment (e.g. uncontrolled diabetes mellitus, history of kidney stones, acute drug toxicity, dementia, delirium, stroke, etc.)

• Meets DSM-IV criteria for alcohol or drug dependence in last 6 months.

• Meets DSM-IV criteria for alcohol or drug abuse in last one month.

• Treatment with clozapine.

• Current positive pregnancy test or not using acceptable method of birth control.

• Meets DSM-IV criteria for current anxiety or mood disorders